Melanoma News and Research

Latest Melanoma News and Research

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.

3 Aug 2010

Patrys secures funding of up to A$15 million to support advancement of clinical products

Patrys Limited (ASX: PAB), a company focused on the development of natural human antibodies for the treatment of cancer, announced today that it has secured up to A$15 million in funding.

3 Aug 2010

OHSU acquires BSD-500 Hyperthermia System

BSD Medical Corporation is pleased to announce that Oregon Health & Science University has acquired a BSD-500 Hyperthermia System. OHSU is a leading university that provides world-class treatment for the most complex health care needs. OHSU has been ranked in U.S. News & World Report's annual rankings as one of America's Best Hospitals for 15 consecutive years and has been recognized in the medical specialties of cancer and endocrinology.

2 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Genta board approves one-for-one hundred reverse stock split

Genta Incorporated announced today that its Board of Directors has approved a one-for-one hundred reverse stock split of Genta's common stock, and that the split will be effective with the open of trading on August 2, 2010. As of that date, the Company's common stock will temporarily trade under the symbol GETAD.OB for 20 business days, at which time the symbol will revert to GETA.OB.

31 Jul 2010

Despite all advancements in melanoma diagnosis, rapid treatment remains critical: Report

Twenty-five years after publishing the mnemonic "ABCD" to facilitate the early diagnosis of melanoma, the group who came up with that moniker says early detection remains a key factor in lowering mortality from malignant melanoma. Darrell S. Rigel, M.D. and colleagues from the Ronald O. Perelman Department of Dermatology at New York University School of Medicine say that, despite all of the advances in melanoma diagnosis, timely recognition, detection, and rapid treatment of melanoma remain critical.

30 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours.

29 Jul 2010

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Pain Therapeutics, Inc., a biopharmaceutical company, today reported second quarter financial results. Net loss for the quarter ended June 30, 2010 was $0.8 million, or $0.02 per share, compared to net loss of $34,000, or $0.00 per share, for the second quarter of 2009. Pain Therapeutics had cash, cash equivalents and marketable securities of $176.2 million, or about $4.14 cash per share, and no debt as of June 30, 2010.

28 Jul 2010

MabCure's MAbs 94% accurate in identifying ovarian cancer

Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.

28 Jul 2010

Obesity linked to rising womb cancer in women: Report

According to a new report from the Charity Cancer Research (CCR) in Britain, the number of women with womb cancer or uterine cancer is on the rise and obesity may be a clue to such rise.

26 Jul 2010

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.

23 Jul 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.

22 Jul 2010

Womb cancer is the fourth most common cancer among UK women: Research

Womb cancer cases are highest ever for over three decades.The number of women diagnosed with womb cancer is at its highest for over 30 years according to new figures published today by Cancer Research UK which show more than 7,530 people now develop the disease each year in the UK.

22 Jul 2010

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.

20 Jul 2010

Diffused ultraviolet radiation penetrates beach umbrellas

A team of researchers from the University of Valencia (UV) has proven that 34% of ultraviolet radiation filters through under beach umbrellas. According to what is published in the journal Photochemistry and Photobiology, umbrellas intercept the full direct flow that comes from the Sun, but not the diffused radiation that penetrates through from the sides.

20 Jul 2010

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer-cancer stem cells (CSCs).The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.

17 Jul 2010

NEOP receives stockholder approval to increase company shares to 205 milliion

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.

17 Jul 2010

Melanoma News and Research

Latest Melanoma News and Research

Vical second-quarter revenues decrease to $2.1 million

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

Patrys secures funding of up to A$15 million to support advancement of clinical products

OHSU acquires BSD-500 Hyperthermia System

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Genta board approves one-for-one hundred reverse stock split

Despite all advancements in melanoma diagnosis, rapid treatment remains critical: Report

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

MabCure's MAbs 94% accurate in identifying ovarian cancer

Obesity linked to rising womb cancer in women: Report

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Womb cancer is the fourth most common cancer among UK women: Research

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Diffused ultraviolet radiation penetrates beach umbrellas

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

NEOP receives stockholder approval to increase company shares to 205 milliion

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Melanoma News and Research

Latest Melanoma News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in